<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491192</url>
  </required_header>
  <id_info>
    <org_study_id>1575</org_study_id>
    <nct_id>NCT00491192</nct_id>
  </id_info>
  <brief_title>Normothermia in Patients With Acute Cerebral Damage</brief_title>
  <official_title>Normothermia in Patients With Acute Cerebral Damage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of our study is to verify wherever normothermia (achieved with diclofenac&#xD;
      administration) may improve intracranial pressure control and may limit secondary cerebral&#xD;
      damage thus positively influencing outcome in patients with acute cerebral damage admitted to&#xD;
      ICU.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pyrexia can exacerbate ischemic neuronal damage and physiological dysfunction after traumatic&#xD;
      brain injury and subarachnoid hemorrhage.Fever also represent an important issue occurring in&#xD;
      78% of patients with acute cerebral damage admitted to intensive care unit (ICU). For those&#xD;
      patients, normothermia is actually recommended in order to reduce secondary cerebral damage&#xD;
      and to control intracranial pressure, that are known to worsen long term prognosis. Our&#xD;
      primary endpoint is to maintain normothermia in patients with acute cerebral damage (axillary&#xD;
      temperature &lt; 38°C or internal temperature &lt; 38,8°C) administering diclofenac. We will also&#xD;
      investigate the corresponding behaviour of intracranial pressure and cerebral perfusion&#xD;
      pressure.&#xD;
&#xD;
      Comparison(s): We will compare two different doses of subcutaneous diclofenac (0,35 mg/kg -&#xD;
      1/3 a vial - vs 0,5 mg/Kg - 1/2 vial) to continuous intravenous of 0,48 mg/kg diclofenac for&#xD;
      12 hours.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2007</start_date>
  <completion_date>June 2009</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maintenance of normothermia</measure>
    <time_frame>within 14 days from ICU admission</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Behaviour of intracranial pressure and cerebral perfusion pressure. Influence on six month outcome.</measure>
    <time_frame>Within 14 days from ICU admission/Six months</time_frame>
  </secondary_outcome>
  <condition>Traumatic Brain Injury</condition>
  <condition>Subarachnoid Hemorrhage</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with severe traumatic injury or subarachnoid hemorrhage in coma (GCS&lt;8),&#xD;
             intubated, mechanically ventilated with intracranial pressure (ICP) and invasive&#xD;
             arterial pressure monitoring&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Know adverse reactions with NSAI&#xD;
&#xD;
          -  Platelets count &lt; 20,000/dl&#xD;
&#xD;
          -  Gastric or duodenal ulceration in active phase&#xD;
&#xD;
          -  Hepatic insufficiency, cirrhosis or previous liver transplant&#xD;
&#xD;
          -  Acute or chronic renal insufficiency&#xD;
&#xD;
          -  Coronary insufficiency, acute myocardial infarct in the previous 6 month&#xD;
&#xD;
          -  Barbiturate coma&#xD;
&#xD;
          -  Patients in therapy with acetylsalicylic acid, lithium, digoxin, methotrexate and&#xD;
             cyclosporin.&#xD;
&#xD;
          -  Known or suspected pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nino Stocchetti, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ospedale Maggiore Policlinico Mangiagalli e Regina Elena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nino Stocchetti, MD</last_name>
    <phone>0039.02.5503.5517</phone>
    <email>stocchet@policlinico.mi.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laura Ghisoni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katia Canavesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <last_update_submitted>September 19, 2007</last_update_submitted>
  <last_update_submitted_qc>September 19, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2007</last_update_posted>
  <keyword>Fever</keyword>
  <keyword>Acute cerebral damage</keyword>
  <keyword>Normothermia</keyword>
  <keyword>Diclofenac</keyword>
  <keyword>ICU</keyword>
  <keyword>Outcome</keyword>
  <keyword>Intracranial pressure</keyword>
  <keyword>Cerebral perfusion pressure</keyword>
  <keyword>Traumatic brain injury</keyword>
  <keyword>Subarachnoid hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

